Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Qurient.

    Client Virtual Booth

    QURIENT

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Qurient
    korearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    C-dong 801, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13487, Korea
    Telephone
    Telephone
    +82-31-8060-1600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.qurient.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent

    Details:

    Under the terms of the license agreement TB Alliance obtains the exclusive worldwide license to develop and commercialize Q203 (telacebec), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis and some NTM infections.


    Lead Product(s): Telacebec

    Therapeutic Area: Infections and Infectious Diseases Product Name: Q203

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: TB Alliance

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement February 03, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Qurient Announces Dosing of First Patient in Q702 in Combination with Keytruda® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid...

    Details:

    Q702 is an orally available novel Axl/Mer/CSF1R inhibitor and is designed to modulate innate immune components leading to T cell activation. Q702 was also shown to increase antigen presentation in the tumor cells demonstrating dual mode of action.


    Lead Product(s): Q702,Pembrolizumab

    Therapeutic Area: Oncology Product Name: Q702

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 30, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors

    Details:

    Q901 is a highly selective CDK7 inhibitor that disrupts tumor cells division cycle progression and blocks DNA damage repair, resulting in tumor cell apoptosis.


    Lead Product(s): Q901

    Therapeutic Area: Oncology Product Name: Q901

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Qurient Announces Publication in New England Journal of Medicine of Phase 2 Data for Telacebec

    Details:

    Clinical data supports continued development of telacebec toward the first universal regimen to overcome tuberculosis regardless of drug resistance status.


    Lead Product(s): Telacebec

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 26, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search